Wallerian Degeneration

Introduction

• Bradley and Daroff's Neurology in Clinical Practice
• Adams and Victor's Principles of Neurology, 12th Ed

When Does Wallerian Degeneration Occur?

• Miller's Review of Orthopaedics, 9th Edition
• Rockwood and Green's Fractures in Adults, 10th Edition, 2025

Mechanism / Pathophysiology

Trigger

Molecular Events (Distal Segment)

1. Rapid calcium influx through the disrupted axonal plasma membrane activates calpain proteases, initiating programmed axonal death (sharing features with apoptosis).
2. Leukocyte recruitment and cytokine-mediated signaling cascade is initiated.
3. Synthesis of neurotrophins, chemokines, extracellular matrix molecules, proteolytic enzymes, and interleukins is upregulated.
4. By Day 3: Schwann cells retract from the nodes of Ranvier.
5. Activated Schwann cells and macrophages begin to phagocytose axon and myelin debris.
6. The entire distal axonal process of WD takes approximately 1 week.

• Bradley and Daroff's Neurology in Clinical Practice
• Adams and Victor's Principles of Neurology, 12th Ed

Changes Distal to the Injury

• Rockwood and Green's Fractures in Adults, 10th Ed
• Bradley and Daroff's Neurology in Clinical Practice

Changes Proximal to the Injury

1. Limited retrograde degeneration: The axon breaks down back to the first node of Ranvier proximal to the injury site (1-2 nodes).
2. Chromatolysis (central chromatolysis): The cell body undergoes:
   • Breakup and dispersion of the rough endoplasmic reticulum (Nissl substance)
   • Eccentric displacement of the cell nucleus
   • Increased nuclear expression of transcription factors
   • Switch in gene expression pattern from axon maintenance to protein synthesis (regeneration mode)
3. In very proximal injuries (e.g., proximal arm amputation), the cell body itself may undergo apoptosis.

Electrodiagnostic Significance

• Before WD is complete (within the first 3-5 days): The distal nerve segment retains electrical excitability. Nerve conduction studies may appear falsely normal distally.
• After WD is complete (beyond Day 7-10): Nerve conduction studies show loss of SNAP and CMAP amplitudes distally.
• EMG: Fibrillation potentials and positive sharp waves appear in denervated muscle, typically 2-3 weeks after injury.
• This is why electrodiagnostic studies are ideally performed 3-4 weeks after injury for accurate severity grading.
• Cummings Otolaryngology (relevant physiologic principle); Miller's Review of Orthopaedics

Nerve Regeneration After Wallerian Degeneration

1. Axons sprout from the proximal stump, crossing the injury site (a major barrier even if only 1-2 mm across).
2. Growth rate: approximately 1 mm/day (or 1 inch/month, clinically used).
3. Regenerating axons follow contact guidance from the Bands of Büngner within endoneurial tubes.
4. ~50% of fibers fail to cross the repair site, forming a neuroma-in-continuity.
5. Problems with regeneration include poor type specificity (motor axons entering sensory tubes) and poor topographical specificity (misdirection to wrong territory) - reasons why fascicular matching during nerve repair is important.
6. Hoffman-Tinel sign (advancing Tinel) is the clinical marker of axonal regeneration.
7. Regenerated axons remain abnormal - reduced fiber diameter and hence slower conduction velocity compared to normal.

• Rockwood and Green's Fractures in Adults, 10th Ed

Orthopaedic Relevance and Clinical Points

1. Timing of surgery: There is strong evidence (experimental and clinical) that delay of repair beyond 1-2 months profoundly deteriorates the quality of nerve regeneration. Early repair (<3 months) is preferred for Sunderland Grade III-V injuries.
2. Upper limit of repair: After ~4 years from injury, significant motor recovery is unlikely even with surgical intervention.
3. Factors affecting outcome: Age (elderly fare worse), metabolic comorbidities (diabetes, renal failure), mechanism of injury (scalpel laceration better than chain-saw), and distance from injury to target organ.
4. Experimental strategies: Pharmacologic agents to slow WD, electrical stimulation to promote axon growth, gene therapy to increase neurotrophic factors, and polyethylene glycol fusion of divided axons (within 24 hours) to prevent WD entirely - these remain experimental.

• Rockwood and Green's Fractures in Adults, 10th Ed

Wallerian Degeneration vs. Other Degenerative Processes

• Adams and Victor's Principles of Neurology, 12th Ed

Summary

• Rockwood and Green's Fractures in Adults, 10th Edition, 2025
• Miller's Review of Orthopaedics, 9th Edition
• Bradley and Daroff's Neurology in Clinical Practice
• Adams and Victor's Principles of Neurology, 12th Edition

Wallerian Degeneration

(10 Marks - RGUHS Orthopaedic PG Exam)

1. Definition and Historical Background

2. When Does Wallerian Degeneration Occur?

• Miller's Review of Orthopaedics, 9th Ed
• Rockwood and Green's Fractures in Adults, 10th Ed, 2025

3. Pathophysiology - Molecular Trigger

1. Rapid calcium and sodium influx through the disrupted axonal plasma membrane
2. Calcium activates calpain proteases, initiating programmed axonal death (shares features with apoptosis)
3. Leukocyte recruitment and cytokine-mediated signaling cascade is initiated
4. Upregulation of neurotrophins, chemokines, extracellular matrix molecules, proteolytic enzymes, and interleukins
5. Upregulation of c-Jun protein in Schwann cells - drives transition from myelin-producing cells to repair cells

• Bradley and Daroff's Neurology in Clinical Practice

4. Changes DISTAL to the Injury Site

• Rockwood and Green's Fractures in Adults, 10th Ed
• Adams and Victor's Principles of Neurology, 12th Ed

5. Changes PROXIMAL to the Injury Site

• Breakup and dispersion of Nissl substance (rough endoplasmic reticulum)
• Eccentric displacement of the cell nucleus
• Increased nuclear expression of transcription factors
• Switch in gene expression from axon maintenance mode → protein synthesis/regeneration mode
• This represents the cell body preparing for axonal regeneration

• Bradley and Daroff's Neurology in Clinical Practice

6. Electrodiagnostic Significance (Important for Exams)

• Miller's Review of Orthopaedics, 9th Ed

7. Nerve Regeneration After Wallerian Degeneration

1. Axonal sprouting from proximal stump - begins 2-3 weeks after injury in humans
2. Axons must cross the injury/repair site (a significant barrier even if only 1-2 mm)
3. Rate of regeneration: ~1 mm/day (clinically: 1 inch/month)
4. Regenerating axons follow the Bands of Büngner within endoneurial tubes
5. ~50% of fibers fail to cross the repair site, forming a neuroma-in-continuity
6. Problems limiting full recovery:
   • Poor type specificity (motor axons entering sensory endoneurial tubes)
   • Poor topographical specificity (misdirection to wrong target territory)
7. Hoffman-Tinel sign (advancing Tinel) = clinical marker of regenerating axons
8. Regenerated axons have reduced fiber diameter and slower conduction velocity compared to pre-injury nerves

• Rockwood and Green's Fractures in Adults, 10th Ed

8. Comparison with Other Degenerative Processes

• Adams and Victor's Principles of Neurology, 12th Ed

9. Orthopaedic Clinical Relevance

1. Timing of surgical repair: Experimental and clinical evidence strongly supports that delay of repair beyond 1-2 months profoundly deteriorates regeneration quality - due to proximal stump losing ability to grow AND distal stump losing capacity to support axonal growth. Early repair (<3 months) is preferred for Sunderland III-V injuries.
2. Upper limit for repair: After approximately 4 years from injury, significant motor recovery is unlikely regardless of surgical intervention.
3. Factors affecting recovery outcome:
   • Age (elderly patients fare worse)
   • Metabolic comorbidities (diabetes, renal failure)
   • Mechanism of injury (scalpel laceration > chain-saw laceration in prognosis)
   • Distance from injury site to target organ (longer = worse)
   • Early recovery of motor/sensory function (<3 months) = good prognostic sign
4. Experimental strategies (not yet in clinical use):
   • Pharmacologic agents to slow WD
   • Electrical stimulation to promote axon growth
   • Gene therapy to increase neurotrophic factor production
   • Polyethylene glycol (PEG) fusion of divided axon ends within 24 hours to prevent WD entirely - initial experimental results are encouraging

• Rockwood and Green's Fractures in Adults, 10th Ed

10. Summary

• Rockwood and Green's Fractures in Adults, 10th Edition, 2025
• Miller's Review of Orthopaedics, 9th Edition
• Bradley and Daroff's Neurology in Clinical Practice
• Adams and Victor's Principles of Neurology, 12th Edition

Postoperative Analgesics

(10 Marks - RGUHS Orthopaedic PG Exam)

1. Introduction

• Impaired mobilization and physiotherapy
• Pulmonary complications (splinting, atelectasis)
• Deep vein thrombosis
• Chronic post-surgical pain (central sensitization)
• Prolonged hospital stay and reduced patient satisfaction

• Miller's Anesthesia, 10th Edition
• Miller's Review of Orthopaedics, 9th Edition

2. Concept of Multimodal Analgesia

• Synergistic analgesia
• Reduced opioid consumption and opioid-related side effects
• Earlier mobilization and return of function
• Reduced length of hospital stay

"The analgesic benefits of controlling postoperative pain are generally maximized when a multimodal strategy to facilitate the patient's convalescence is implemented."

• Miller's Anesthesia, 10th Ed

3. Classification of Postoperative Analgesics

Postoperative Analgesics
├── A. Systemic Agents
│   ├── Opioids (morphine, fentanyl, tramadol)
│   ├── Non-opioids
│   │   ├── Paracetamol (acetaminophen)
│   │   ├── NSAIDs (ketorolac, ibuprofen, diclofenac)
│   │   └── COX-2 inhibitors (celecoxib, parecoxib)
│   └── Adjuvants
│       ├── Gabapentinoids (gabapentin, pregabalin)
│       ├── Ketamine (NMDA antagonist)
│       └── Alpha-2 agonists (clonidine, dexmedetomidine)
└── B. Regional / Locoregional Techniques
    ├── Neuraxial (epidural, intrathecal)
    ├── Peripheral nerve blocks
    └── Local infiltration / periarticular injection

4. Systemic Analgesics

A. Opioids

• No analgesic ceiling (theoretically), but limited in practice by side effects
• Wide inter-subject variability in dose-response relationship
• Routes: IV (most reliable onset), oral, subcutaneous, transmucosal, intramuscular
• IV/IM used for moderate-to-severe pain; transition to oral once tolerating diet

• Nausea/vomiting, sedation, respiratory depression, constipation, pruritus, urinary retention
• Risk of dependence and tolerance with prolonged use

• Patient self-administers IV opioid bolus via a programmable pump
• Eliminates administrative delays and compensates for inter-patient variability
• Settings: demand dose, lockout interval (typically 5-10 min), 1-hour and 4-hour limits
• Shown to decrease postoperative pain, drug use, sedation, and pulmonary complications compared to PRN regimens
• Well accepted by patients; improves satisfaction
• Barash, Cullen, and Stoelting's Clinical Anesthesia, 9th Ed
• Miller's Anesthesia, 10th Ed

B. Paracetamol (Acetaminophen)

• Acts centrally via activation of descending serotonergic pathways and inhibition of prostaglandin synthesis
• Has antipyretic and mild anti-inflammatory properties
• Maximum dose: 4 g/day in adults (reduce in hepatic disease, elderly, malnourished)
• Available as: oral, rectal suppository, and IV formulation (FDA approved 2011)
• IV acetaminophen after joint arthroplasty: decreased pain scores, less opioid use, longer time to morphine rescue, greater patient satisfaction (Sinatra et al.)
• Meta-analysis of 865 patients (4 RCTs) after total hip arthroplasty showed addition of IV acetaminophen to multimodal analgesia reduced opioid consumption and pain scores
• AAHKS/AAOS/ASRA strong recommendation: IV or oral acetaminophen does not increase risk of complications following primary total joint arthroplasty (TJA)
• Miller's Anesthesia, 10th Ed
• Miller's Review of Orthopaedics, 9th Ed

C. NSAIDs and COX-2 Inhibitors

• An oral NSAID given preoperatively and/or early postoperatively reduces pain and opioid consumption after primary TJA
• IV ketorolac given preoperatively, intraoperatively, or within 24 hours postoperatively reduces pain and opioid consumption within the first 48 hours

• Ketorolac 30 mg IM: NNT ~3.5 (very effective single-agent analgesic)
• Ibuprofen 400 mg: NNT ~3.0
• (Lower NNT = greater analgesic efficacy)

• Fewer GI complications and minimal platelet inhibition
• Cardiovascular risk with long-term use (rofecoxib withdrawn)
• Short-term perioperative celecoxib is safe and noninferior to naproxen/ibuprofen for cardiovascular risk (RCT of 24,081 patients)
• Perioperative NSAIDs not associated with increased risk of postoperative MI after TJA
• Miller's Anesthesia, 10th Ed
• Miller's Review of Orthopaedics, 9th Ed

D. Gabapentinoids (Gabapentin and Pregabalin)

• In the perioperative period: gabapentinoids do NOT reduce postoperative pain, but pregabalin reduces opioid consumption
• After discharge: pregabalin reduces postoperative pain, neuropathic pain, and opioid consumption after TJA; gabapentin does NOT
• Pregabalin is 2-4 times more potent than gabapentin as an analgesic
• Gabapentin: also reduces postoperative delirium in thoracic surgery (900 mg preoperatively)
• Miller's Review of Orthopaedics, 9th Ed
• Barash, Cullen, and Stoelting's Clinical Anesthesia, 9th Ed

E. Ketamine (NMDA Receptor Antagonist)

• Blocks N-methyl-D-aspartate (NMDA) receptors, preventing central sensitization and "wind-up"
• Subanesthetic doses (0.05-0.3 mg/kg/h IV infusion) used as adjuvant to opioids
• Benefits: reduces opioid consumption, attenuates opioid-induced hyperalgesia, has anti-inflammatory effects
• Small doses added to morphine PCA reduce morphine consumption and improve respiratory parameters
• Can be administered IV, IM, or epidurally
• Side effects: dysphoria, hallucinations (reduced at low doses), increased secretions

5. Regional / Locoregional Analgesic Techniques

A. Epidural Analgesia (Neuraxial)

• Gold standard for major lower limb, pelvic, and spine surgery
• Catheter placed at a level congruent with the surgical dermatome (catheter incision-congruent analgesia = optimal results)
• Drugs: local anesthetics (bupivacaine, ropivacaine) ± opioids (morphine, fentanyl) ± adjuvants (clonidine, epinephrine)
• Benefits: superior pain control, reduced stress response, earlier mobilization, preserved bowel function
• Complications: hypotension (commonest), urinary retention, motor block, pruritus, respiratory depression (with opioids), rare neurologic injury (<4 in 10,000)
• Lumbar epidural for lower limb surgery causes more frequent quadriceps motor block and may impair early ambulation

B. Peripheral Nerve Blocks (Orthopaedic Specific)

Best combination for TKA: ACB + iPACK provides best perioperative pain relief and postoperative function. ACB single injection is as effective as indwelling catheter (catheters dislodge during ambulation).

• Miller's Review of Orthopaedics, 9th Ed

6. WHO Analgesic Ladder (Modified for Postoperative Use)

7. Special Considerations in Orthopaedic Surgery

8. Monitoring of Postoperative Analgesia

• Pain scores at rest and with activity (VAS or NRS 0-10) - documented regularly
• Vital signs: HR, BP, respiratory rate, SpO2
• Opioid-specific: sedation score, respiratory rate, SpO2
• Regional technique-specific: motor block assessment, site inspection
• PCA-specific: demand dose, lockout interval, successful/unsuccessful attempts, total drug delivered

9. Summary Table

10. Conclusion

• Miller's Anesthesia, 10th Edition
• Miller's Review of Orthopaedics, 9th Edition (AAHKS/AAOS/ASRA guidelines)
• Barash, Cullen & Stoelting's Clinical Anesthesia, 9th Edition
• Rockwood and Green's Fractures in Adults, 10th Edition, 2025